09.11.14
San Diego, Calif.-based SpectraScience Inc. has added a U.K. site to its clinical trial for the evaluation of the colon application of the Wavstat4 optical biopsy system. The trial, a MORDIS (modified resect and discard) evaluation, will now also be conducted at St. James NHS (National Health Service) University Hospital in Leeds, England. In the United Kingdom, the Wavstat trial is conducted in collaboration with the Colorectal Therapies Healthcare Technology Cooperative based at St. James University Hospital, Leeds. Venkat Subramanian, M.D., will be the principal investigator for the MORDIS trial in the United Kingdom.
The NHS, the United Kingdom’s healthcare system, recently was voted as the world’s best healthcare system based on quality access and efficiency by the Commonwealth Fund (a New York, N.Y.-based, non-partisan foundation that supports independent research on health and social issues). The National Institute for Health Research serves as the liaison between industry and the clinicians of the National Health Service, and facilitates clinical evaluations of new products and technologies of interest to the NHS.
Providing NHS clinical validation of Wavstat4 will enable SpectraScience to enter into the National Institutes of Health and Clinical Excellence (NICE) medtech evaluation program this fall.
NICE offers guidance on use of medical technology across the NHS, said Michael Oliver, SpectraScience’s president and CEO: “With the successful implementation of the clinical evaluation in United Kingdom, we can quickly establish both the clinical and economic value for the NHS. Our system is faster for clinicians, safer for patients and less expensive than pathology for the health system.
“Our Wavstat4 optical biopsy system provides a fast, safe, accurate and cost-effective way to differentiate benign and cancerous lesions in the colon with a 96 percent negative predictive value,” Oliver added. “We look forward to working with Dr. Subramanian, St. James University Hospital and to eventually make the Wavstat4 optical biopsy system available for colorectal cancer screening throughout the NHS.”
SpectraScience makes light technologies to detect and diagnose cancers.
The NHS, the United Kingdom’s healthcare system, recently was voted as the world’s best healthcare system based on quality access and efficiency by the Commonwealth Fund (a New York, N.Y.-based, non-partisan foundation that supports independent research on health and social issues). The National Institute for Health Research serves as the liaison between industry and the clinicians of the National Health Service, and facilitates clinical evaluations of new products and technologies of interest to the NHS.
Providing NHS clinical validation of Wavstat4 will enable SpectraScience to enter into the National Institutes of Health and Clinical Excellence (NICE) medtech evaluation program this fall.
NICE offers guidance on use of medical technology across the NHS, said Michael Oliver, SpectraScience’s president and CEO: “With the successful implementation of the clinical evaluation in United Kingdom, we can quickly establish both the clinical and economic value for the NHS. Our system is faster for clinicians, safer for patients and less expensive than pathology for the health system.
“Our Wavstat4 optical biopsy system provides a fast, safe, accurate and cost-effective way to differentiate benign and cancerous lesions in the colon with a 96 percent negative predictive value,” Oliver added. “We look forward to working with Dr. Subramanian, St. James University Hospital and to eventually make the Wavstat4 optical biopsy system available for colorectal cancer screening throughout the NHS.”
SpectraScience makes light technologies to detect and diagnose cancers.